FDA Site Inspection Reports on RCT Irregularities and Misconduct—The Case For Transparency

This Viewpoint reviews notable examples of clinical trial misconduct identified by routine US Food and Drug Administration (FDA) clinical trial site inspections and argues that making inspection reports publicly available on the agency’s and trial registry websites is important to maintaining the integrity of clinical research.

Leave a Reply